查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1421610

骨髓增生性疾病治療市場、份額、規模、趨勢、行業分析報告：按類型、按治療、按最終用途、按地區、按細分市場、預測，2023-2032 年

Myeloproliferative Disorder Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Polycythaemia Vera, Essential Thrombocythemia, Myelofibrosis, Other), By Treatment, By End-Use, By Region, And Segment Forecasts, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，到 2032 年，全球骨髓增生性疾病治療市場規模預計將達到 131.3 億美元。 該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

新藥的供應量正在增加，並且存在強大的潛在治療方法。 這讓人樂觀地認為未來將會出現更有效的治療方法，從而推動市場的興趣和投資。 由於生活方式的改變和人口老化，骨髓增生性疾病的盛行率不斷增加。 這些因素增加了這些疾病的風險人數，並增加了對治療的需求。

此外，大眾對骨髓增生性疾病的認識也不斷提高。 這種意識的提高導致了早期診斷和早期治療，進一步增加了該市場對治療藥物的需求。 此外，為無法耐受 Jakafi 的患者開發治療方案是一個值得注意的趨勢，Jakafi 常用於治療骨髓增生性疾病。 這種二線治療滿足了對 Jakafi 沒有反應的患者的需求，並擴大了市場的潛在患者基礎。

慢性骨髓增生性疾病（MPD）是一組罕見的血液系統惡性腫瘤，其特徵是骨髓和周邊血液中某些血球的異常增生。 這些疾病主要影響骨髓譜系及其前驅細胞，包括紅血球、粒細胞（白血球的一種）和血小板。 這些疾病根據費城染色體的存在或不存在進一步分類。 費城染色體是一種特定的遺傳異常，由 9 號和 22 號染色體之間的易位（遺傳物質交換）引起。 費城染色體的存在是 CML 的標誌。

慢性骨髓增生性疾病是一種複雜的疾病，需要醫療專業人員仔細診斷和治療。 治療選擇包括控制血球數、控制症狀和降低併發症風險的藥物。 在某些情況下，幹細胞移植可被視為一種治療方法。

北美和西歐的骨髓增生性疾病（MPN）發生率高於東亞國家，被認為是由多種因素造成的，包括遺傳傾向、生活方式和環境因素的差異。 儘管大多數 MPN 患者在 60 歲後被診斷出來，但這些疾病可以在任何年齡發生。 美國因其人口眾多、醫療基礎設施先進以及研發投入巨大，可提供MPN創新療法，因此成為MPN藥物最有可能的市場，令人期待。

骨髓增生性疾病治療市場報告亮點

  • 由於病例數增加以及為提高治療效果而加強研發力度，骨髓纖維化領域佔最大比例。
  • 飲食變化和忙碌的生活方式導致癌症病例迅速增加，推動了化療行業的發展
  • 由於其發達的醫療基礎設施以及工業界和學術界在研發方面的積極合作，北美佔據了最大的市場份額。
  • 主要參與者包括諾華 (Novartis)、百時美施貴寶 (Bristol-Myers)、Incyte Corp、武田製藥 (Takeda Pharmaceuticals)、Viatris、艾伯維 (AbbVie) 和梯瓦製藥 (Teva Pharmaceuticals)。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第 4 章全球骨髓增生性疾病治療市場洞察

  • 骨髓增生性疾病治療市場 - 最終用途概況
  • 骨髓增生性疾病治療市場動態
    • 推動者和機會
      • 對有效治療的需求不斷增加
      • 研發和分子理解的進展
    • 抑制因素和挑戰
      • 治療選擇有限
  • PESTEL 分析
  • 骨髓增生性疾病治療市場最終用途趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第五章全球骨髓增生性疾病治療市場（依類型）

  • 主要調查結果
  • 簡介
  • 真性紅血球增多症
  • 原發性血小板增多症
  • 骨髓纖維化
  • 其他

第 6 章全球骨髓增生性疾病治療市場（依治療）

  • 主要調查結果
  • 簡介
  • 化療
  • 免疫治療
  • 幹細胞移植
  • 其他

第 7 章全球骨髓增生性疾病治療市場，依最終用途劃分

  • 主要調查結果
  • 簡介
  • 醫院
  • 專科診所
  • 其他

第 8 章全球骨髓增生性疾病治療市場（按地區）

  • 主要調查結果
  • 簡介
    • 2019-2032 年各地區骨髓增生性疾病治療市場評估
  • 骨髓增生性疾病治療市場 - 北美
    • 北美：骨髓增生性疾病治療市場（依類型），2019-2032 年
    • 北美：骨髓增生性疾病治療市場（以最終用途），2019-2032 年
    • 北美：骨髓增生性疾病治療市場（依治療方式），2019-2032 年
    • 骨髓增生性疾病治療市場 - 美國
    • 骨髓增生性疾病治療市場 - 加拿大
  • 骨髓增生性疾病治療市場 - 歐洲
    • 歐洲：骨髓增生性疾病治療市場（依類型），2019-2032 年
    • 歐洲：骨髓增生性疾病治療市場（以最終用途），2019-2032 年
    • 歐洲：骨髓增生性疾病治療市場（依治療方式），2019-2032 年
    • 骨髓增生性疾病治療市場 - 英國
    • 骨髓增生性疾病治療市場 - 法國
    • 骨髓增生性疾病治療市場 - 德國
    • 骨髓增生性疾病治療市場 - 義大利
    • 骨髓增生性疾病治療市場 - 西班牙
    • 骨髓增生性疾病治療市場 - 荷蘭
    • 骨髓增生性疾病治療市場 - 俄羅斯
  • 骨髓增生性疾病治療市場 - 亞太地區
    • 亞太地區：骨髓增生性疾病治療市場（按類型），2019-2032 年
    • 亞太地區：骨髓增生性疾病治療市場（依最終用途），2019-2032 年
    • 亞太地區：骨髓增生性疾病治療市場（依治療方式），2019-2032 年
    • 骨髓增生性疾病治療市場 - 中國
    • 骨髓增生性疾病治療市場 - 印度
    • 骨髓增生性疾病治療市場 - 馬來西亞
    • 骨髓增生性疾病治療市場 - 日本
    • 骨髓增生性疾病治療市場 - 印度尼西亞
    • 骨髓增生性疾病治療市場 - 韓國
  • 骨髓增生性疾病治療市場 - 中東和非洲
    • 中東和非洲：骨髓增生性疾病治療市場（按類型），2019-2032 年
    • 中東和非洲：骨髓增生性疾病治療市場（以最終用途），2019-2032 年
    • 中東與非洲：骨髓增生性疾病治療市場（依治療方式），2019-2032 年
    • 骨髓增生性疾病治療市場 - 沙烏地阿拉伯
    • 骨髓增生性疾病治療市場 - 阿拉伯聯合大公國
    • 骨髓增生性疾病治療市場 - 以色列
    • 骨髓增生性疾病治療市場 - 南非
  • 骨髓增生性疾病治療市場 - 拉丁美洲
    • 拉丁美洲：骨髓增生性疾病治療市場（按類型），2019-2032 年
    • 拉丁美洲：骨髓增生性疾病治療市場（以最終用途），2019-2032 年
    • 拉丁美洲：骨髓增生性疾病治療市場（依治療方式），2019-2032 年
    • 骨髓增生性疾病治療市場 - 墨西哥
    • 骨髓增生性疾病治療市場 - 巴西
    • 骨髓增生性疾病治療市場 - 阿根廷

第九章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第十章公司簡介

  • AbbVie
  • Bristol-Myers Squibb
  • Incyte Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals
  • Viatris（Mylan N.V.）
Product Code: PM3936

The global myeloproliferative disorders treatment market size is expected to reach USD 13.13 billion by 2032, according to a new study by Polaris Market Research. The report "Myeloproliferative Disorder Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Polycythaemia Vera, Essential Thrombocythemia, Myelofibrosis, Other), By Treatment, By End-Use, By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

There is a growing availability of novel drugs and a strong pipeline of potential treatments. This has created optimism for more effective therapies in the future, driving interest and investment in the market. The rising incidence of myeloproliferative disorders can be attributed to changing lifestyles and an aging population. These factors have contributed to an increase in the number of individuals at risk of developing these conditions, leading to a higher demand for treatments.

Additionally, there is a heightened level of public awareness regarding myeloproliferative disorders. This increased awareness has led to earlier diagnosis and treatment, further fueling the demand for therapies in the market. Furthermore, the development of therapeutic options for patients who are intolerant to Jakafi, a commonly used medication for myeloproliferative disorders, is a notable trend. This second-line treatment approach addresses the needs of patients who may not respond well to Jakafi, expanding the market's potential patient base.

Chronic myeloproliferative disorders (MPDs) are a group of rare hematological malignancies characterized by the abnormal proliferation of certain types of blood cells in the bone marrow and peripheral blood. These disorders primarily affect the myeloid cell line, which includes red blood cells, granulocytes (a type of white blood cell), and platelets, as well as their precursor cells. These disorders are further categorized based on the presence or absence of the Philadelphia chromosome. The Philadelphia chromosome is a specific genetic abnormality resulting from a translocation (exchange of genetic material) between chromosomes 9 and 22. Its presence is a defining characteristic of CML.

Chronic myeloproliferative disorders are complex conditions that require careful diagnosis and management by healthcare professionals. Treatment options may include medications to control blood cell counts, manage symptoms, and reduce the risk of complications. In some cases, stem cell transplantation may be considered as a curative treatment option.

The higher incidence of myeloproliferative disorders (MPNs) in North America & Western Europe compared to East-Asian countries can be attributed to various factors, including differences in genetic predisposition, lifestyle, and environmental factors. While most MPN patients are diagnosed after the age of 60, these disorders can affect individuals of any age. The United States is poised to be the most prominent market for MPN drugs due to its substantial target population, advanced healthcare infrastructure, and significant investments in research and development, leading to the availability of innovative treatments for MPNs.

Myeloproliferative Disorders Treatment Market Report Highlights

  • The myelofibrosis segment held the largest share, owing to rising cases & increased research & development efforts to increase the efficacy of the treatment procedures
  • Chemotherapy segment led the market on account of a surge in cases of cancers due to changes in diet and busier lifestyle
  • North America garnered the largest share due to the presence of well-developed medical infrastructure, & huge industry-academia efforts for research & innovations
  • Key players include Novartis, Bristol-Myers, Incyte Corp, Takeda Pharmaceutical, Viatris, AbbVie, and Teva Pharmaceuticals

Polaris Market Research has segmented the myeloproliferative disorders treatment market report based on type, treatment, end-use, and region:

Myeloproliferative Disorders Treatment, Type Outlook (Revenue - USD Billion, 2023 - 2032)

  • Polycythaemia Vera
  • Essential Thrombocythemia
  • Myelofibrosis
  • Others

Myeloproliferative Disorders Treatment, Treatment Outlook (Revenue - USD Billion, 2023 - 2032)

  • Chemotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

Myeloproliferative Disorders Treatment, End-Use Outlook (Revenue - USD Billion, 2023 - 2032)

  • Hospitals
  • Specialty Clinics
  • Others

Myeloproliferative Disorders Treatment, Regional Outlook (Revenue - USD Billion, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Myeloproliferative Disorder Treatment Market Insights

  • 4.1. Myeloproliferative Disorder Treatment Market - End-Use Snapshot
  • 4.2. Myeloproliferative Disorder Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing demand for effective treatments
      • 4.2.1.2. Advancements in R&D and molecular understanding
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited treatment options
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Myeloproliferative Disorder Treatment Market End-Use Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Myeloproliferative Disorder Treatment Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Polycythaemia Vera
    • 5.3.1. Global Myeloproliferative Disorder Treatment Market, by Polycythaemia Vera, by Region, 2019-2032 (USD Billion)
  • 5.4. Essential Thrombocythemia
    • 5.4.1. Global Myeloproliferative Disorder Treatment Market, by Essential Thrombocythemia, by Region, 2019-2032 (USD Billion)
  • 5.5. Myelofibrosis
    • 5.5.1. Global Myeloproliferative Disorder Treatment Market, by Myelofibrosis, by Region, 2019-2032 (USD Billion)
  • 5.6. Other
    • 5.6.1. Global Myeloproliferative Disorder Treatment Market, by Other, by Region, 2019-2032 (USD Billion)

6. Global Myeloproliferative Disorder Treatment Market, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 6.3. Chemotherapy
    • 6.3.1. Global Myeloproliferative Disorder Treatment Market, by Chemotherapy, by Region, 2019-2032 (USD Billion)
  • 6.4. Immunotherapy
    • 6.4.1. Global Myeloproliferative Disorder Treatment Market, by Immunotherapy, by Region, 2019-2032 (USD Billion)
  • 6.5. Stem Cell Transplantation
    • 6.5.1. Global Myeloproliferative Disorder Treatment Market, by Stem Cell Transplantation, by Region, 2019-2032 (USD Billion)
  • 6.6. Other
    • 6.6.1. Global Myeloproliferative Disorder Treatment Market, by Other, by Region, 2019-2032 (USD Billion)

7. Global Myeloproliferative Disorder Treatment Market, by End-Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Myeloproliferative Disorder Treatment Market, by Hospitals, By Region, 2019-2032 (USD Billion)
  • 7.4. Specialty Clinics
    • 7.4.1. Global Myeloproliferative Disorder Treatment Market, by Specialty Clinics, By Region, 2019-2032 (USD Billion)
  • 7.5. Other
    • 7.5.1. Global Myeloproliferative Disorder Treatment Market, by Other, By Region, 2019-2032 (USD Billion)

8. Global Myeloproliferative Disorder Treatment Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Myeloproliferative Disorder Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Myeloproliferative Disorder Treatment Market - North America
    • 8.3.1. North America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.3.3. North America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.4. Myeloproliferative Disorder Treatment Market - U.S.
      • 8.3.4.1. U.S.: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.5. Myeloproliferative Disorder Treatment Market - Canada
      • 8.3.5.1. Canada: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.4. Myeloproliferative Disorder Treatment Market - Europe
    • 8.4.1. Europe: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.4. Myeloproliferative Disorder Treatment Market - UK
      • 8.4.4.1. UK: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.5. Myeloproliferative Disorder Treatment Market - France
      • 8.4.5.1. France: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.6. Myeloproliferative Disorder Treatment Market - Germany
      • 8.4.6.1. Germany: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.7. Myeloproliferative Disorder Treatment Market - Italy
      • 8.4.7.1. Italy: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.8. Myeloproliferative Disorder Treatment Market - Spain
      • 8.4.8.1. Spain: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.9. Myeloproliferative Disorder Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.10. Myeloproliferative Disorder Treatment Market - Russia
      • 8.4.10.1. Russia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.5. Myeloproliferative Disorder Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.4. Myeloproliferative Disorder Treatment Market - China
      • 8.5.4.1. China: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.5. Myeloproliferative Disorder Treatment Market - India
      • 8.5.5.1. India: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.6. Myeloproliferative Disorder Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.7. Myeloproliferative Disorder Treatment Market - Japan
      • 8.5.7.1. Japan: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.8. Myeloproliferative Disorder Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.9. Myeloproliferative Disorder Treatment Market - South Korea
      • 8.5.9.1. South Korea: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.6. Myeloproliferative Disorder Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.4. Myeloproliferative Disorder Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.5. Myeloproliferative Disorder Treatment Market - UAE
      • 8.6.5.1. UAE: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.6. Myeloproliferative Disorder Treatment Market - Israel
      • 8.6.6.1. Israel: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.7. Myeloproliferative Disorder Treatment Market - South Africa
      • 8.6.7.1. South Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.7. Myeloproliferative Disorder Treatment Market - Latin America
    • 8.7.1. Latin America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.4. Myeloproliferative Disorder Treatment Market - Mexico
      • 8.7.4.1. Mexico: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.5. Myeloproliferative Disorder Treatment Market - Brazil
      • 8.7.5.1. Brazil: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.6. Myeloproliferative Disorder Treatment Market - Argentina
      • 8.7.6.1. Argentina: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bristol-Myers Squibb
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Incyte Corporation
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Novartis AG
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Takeda Pharmaceutical Company Limited
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Teva Pharmaceuticals
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Viatris (Mylan N.V.)
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development

List of Tables

  • Table 1 Global Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 3 Global Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 4 Myeloproliferative Disorder Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 7 North America: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 8 U.S.: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 10 U.S.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 11 Canada: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 13 Canada: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 14 Europe: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 16 Europe: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 17 UK: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 19 UK: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 20 France: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 22 France: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 23 Germany: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 25 Germany: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 26 Italy: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 28 Italy: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 29 Spain: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 31 Spain: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 35 Russia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 37 Russia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 41 China: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 43 China: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 44 India: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 46 India: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 50 Japan: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 52 Japan: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 56 South Korea: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 58 South Korea: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 65 UAE: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 67 UAE: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 68 Israel: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 70 Israel: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 71 South Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 73 South Africa: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 74 Latin America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 76 Latin America: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 77 Mexico: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 79 Mexico: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 80 Brazil: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 82 Brazil: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 83 Argentina: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 85 Argentina: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Myeloproliferative Disorder Treatment Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Myeloproliferative Disorder Treatment Market, by Treatment, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Myeloproliferative Disorder Treatment Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by End-Use
  • Figure 11. Global Myeloproliferative Disorder Treatment Market, by End-Use, 2022 & 2032 (USD Billion)
  • Figure 12. Myeloproliferative Disorder Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Myeloproliferative Disorder Treatment Market